Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | BUB1 | O43683 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551469 | 0.87 | L3MBTL1 (0.43) | HPGDALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1552563 | 0.84 | ALDH1A1 (0.36) | HPGDALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL1551486 | 0.83 | MAPT (0.36) | HPGDALDH1A1LMNAPOLBHTT | |
| SCHEMBL1552074 | 0.82 | SMN1; SMN2 (0.39) | HPGDALDH1A1KDM4ELMNAHTT | |
| SCHEMBL1552794 | 0.79 | HPGD (0.37) | HPGDALDH1A1BUB1KDM4ELMNA | |
| SCHEMBL1552744 | 0.79 | HPGD (0.39) | HPGDALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL1551484 | 0.77 | CHRM3 (0.40) | HPGDKDM4EGAAHTTHSD17B10 | |
| SCHEMBL1552499 | 0.75 | EPHX1 (0.42) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3786257 | 0.74 | ACHE (0.36) | HPGDALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL1552500 | 0.73 | ASAH1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858613-B2 | Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-12-28 | — | — | US | claimed |
| US-7858613-B2 | Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | ABCB1, DHFR, DHPS | HPGD 59/4885ALDH1A1 613/4885BUB1 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.